Designing antibodies as therapeutics
- PMID: 35868279
- DOI: 10.1016/j.cell.2022.05.029
Designing antibodies as therapeutics
Abstract
Antibody therapeutics are a large and rapidly expanding drug class providing major health benefits. We provide a snapshot of current antibody therapeutics including their formats, common targets, therapeutic areas, and routes of administration. Our focus is on selected emerging directions in antibody design where progress may provide a broad benefit. These topics include enhancing antibodies for cancer, antibody delivery to organs such as the brain, gastrointestinal tract, and lungs, plus antibody developability challenges including immunogenicity risk assessment and mitigation and subcutaneous delivery. Machine learning has the potential, albeit as yet largely unrealized, for a transformative future impact on antibody discovery and engineering.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Both authors are current employees of Genentech, a member of the Roche Group, and Roche stockholders. The Roche Group develops and commercializes therapeutics including antibodies.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical